<DOC>
	<DOCNO>NCT01139918</DOCNO>
	<brief_summary>This exploratory study use identify question part new QoL questionnaire patient psoriasis psoriatic arthritis determine sample size need validation . The new questionnaire global QoL questionnaire take account impact psoriasis psoriatic arthritis QoL . STUDY OBJECTIVES - To evaluate influence psoriasis psoriatic arthritis patient 's answer QoL question DLQI , HAQ , EQ-5D , FACIT-fatigue SF-36 . - To identify equal number question DLQI , HAQ , EQ-5D , FACIT-fatigue SF-36 answer mostly influence either psoriatic arthritis psoriasis .</brief_summary>
	<brief_title>Exploratory Study Quality Life Patient With Moderate Psoriasis Moderate Psoriatic Arthritis</brief_title>
	<detailed_description>This study recruit three cohort 40 patient : moderate psoriatic arthritis moderate psoriasis , mild psoriatic arthritis moderate psoriasis , moderate psoriatic arthritis mild psoriasis . Eligible patient fill follow questionnaire : Dermatology Life Quality Index ( DLQI ) , Health Assessment Questionnaire ( HAQ ) , EQ-5D , Functional Assessment Chronic Illness Therapy-Fatigue ( FACIT-fatigue ) 36-Item Short Form Health Survey Questionnaire ( SF-36 ) . In addition , patient ask 4 point Likert scale much answer question relate impact skin disease psoriatic arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<criteria>Patient plaque psoriasis psoriatic arthritis either : Moderate psoriatic arthritis moderate psoriasis define : [ psoriatic arthritis either 37 joint show sign synovitis OR BASDAI 24 ] AND [ 3 less 10 % body surface area involve psoriasis ] ( COHORT A ) OR Mild psoriatic arthritis Moderate psoriasis define : [ psoriatic arthritis either 12 joint show sign synovitis OR BASDAI great 0 less 2 ] AND [ 3 less 10 % body surface area involve psoriasis ] ( COHORT B ) OR Moderate psoriatic arthritis Mild psoriasis define : [ psoriatic arthritis either 37 joint show sign synovitis OR BASDAI 24 ] AND [ 0 less 3 % body surface area involve psoriasis ] ( COHORT C ) Patient 18 year old . Patient capable read understand French English questionnaire . Patient capable give informed consent . Patient presence eythrodermic , pustular guttate psoriasis . Patient another non psoriatic arthropathy ( osteoarthritis ) could significant impact QoL related psoriatic arthritis Patient another non psoriatic dermatosis could significant impact QoL related psoriasis Patient comorbidity severity could significant impact QoL Patient significant flareup psoriasis psoriatic arthritis within 90 day Day 0 Patient receive investigational drug within four week prior Day 0 Patient treat systemic antipsoriatic drug steroid , retinoids , cyclosporine , PUVA therapy within four week prior Day 0 . Methotrexate , sulphasalazine leflunomide allow study long patient stable dose within 90 day Day 0 . Patient treat ultraviolet light therapy ( UVB , nbUVB ) within two week prior Day 0 Patient use biologics ( etanercept , adalimumab , infliximab , abatacept , ustekinumab ) within 180 day Day 0 Patient currently pregnant lactate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>psoriatic arthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Quality life</keyword>
</DOC>